Building a Global Price Strategy: How Thelansis Helped a Biopharma Set the Right Launch Price Across 15 Markets
Background: A biopharma company was preparing to launch a first-in-class therapy in immunology TA. The asset showed strong clinical promise, but its commercial team faced a familiar challenge: every ...
Optimizing Biotech Investment Strategy in an Uncertain Market Landscape
Introduction: A US-based mid-size biotech firm was preparing for its upcoming investment cycle to broaden its therapeutic area focus. The team had strong scientific instincts but lacked a unified, ev ...
Strengthening Global Market Access Readiness Through Early Payer & HTA Planning
Introduction: A global biopharma company preparing to advance towards asset commercialisation approached Thelansis with a clear priority that they wanted to enter multiple markets with confidence tha ...
How Thelansis Supported a Mid-Sized Biopharma Company in Out-Licensing Their Novel IPF Asset
Introduction: During 2024, a mid-sized biopharma company from the European region was developing a novel systematic therapy for the treatment of IPF, seeking an evidence-backed structured partnership ...
Optimizing Multi-channel Distribution and Inventory Agility in Pharmaceutical Industry through Demand-Based Forecasting
Introduction: The pharma ecosystem is quite complex, wherein companies operate across various channels, ranging from hospital procurement networks to retail pharmacies. While this expands their marke ...
Smart Pipeline Decisions: AI-Powered Indication Prioritization for Oncology TA
Background: In the current scenario, the competitive landscape of oncology TA, where innovation moves rapidly, pharma companies face intense pressure to optimize their pipeline investments. With hund ...
Mapping the Future: Identifying High-value Therapy Area Strategy for Emerging Markets
Background: In an evolving global disease landscape, identifying the right therapy areas or indication setting for investment is a strategic move that defines a company's growth trajectory, especiall ...
The Analogue Advantage: A Smarter Way to derive the market uptake and New Product revenue Forecast
Background: Launching a new therapy in the oncology space is one of the most complex and challenging in the pharma and biotech industries. With evolving treatment landscapes, shifting market dynamics ...
From Evidence to Impact: How Thelansis Accelerated a Rare Disease Submission
Introduction: In recent years, the healthcare landscape has evolved toward an evidence-based, patient-centric architecture. Although conventional clinical trials remain the gold standard, they do not ...
Anticipating the Next Move: AI at the Core of Competitive Intelligence
Introduction: In today's competitive pharmaceutical industry, success relies on anticipating market changes. With rapidly growing data sources, AI-powered data analytics solutions, and predictive mod ...